PMID: 2106347Feb 23, 1990Paper

Comparative effects of simvastatin (MK-733) and pravastatin (CS-514) on hypercholesterolemia induced by cholesterol feeding in rabbits

Biochimica Et Biophysica Acta
F IshidaT Kamei

Abstract

The preventive effects of simvastatin (MK-733) and pravastatin (CS-514), 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors, on hypercholesterolemia induced by 0.25% cholesterol feeding were compared in rabbits. MK-733 (6, 2 and 0.7 mg/kg) was found to prevent the increase in serum total cholesterol levels dose-dependently. High dose CS-514 (18 mg/kg) also limited the increase in the cholesterol levels, but medium (6 mg/kg) and low doses (2 mg/kg) of CS-514 were ineffective in preventing it. MK-733 inhibited the increase in VLDL and LDL cholesterol levels dose-dependently. MK-733 suppressed the increase in serum phospholipid levels. MK-733 inhibited the accumulation of cholesterol in the liver. The high dose of CS-514 also limited it. High dose MK-733 (6 mg/kg) reduced the cholesterol concentration in gallbladder bile. Neither MK-733 nor CS-514 affected bile acid excretion in the gallbladder bile. High dose MK-733 decreased the lithogenic index. MK-733 increased the number of LDL receptors, and high dose CS-514 also increased it. The suppressive effect of CS-514 on serum cholesterol levels at 18 mg/kg was found to be less than that of MK-733 at 0.7 mg/kg.

References

Feb 15, 1989·Biochemical and Biophysical Research Communications·J I GermershausenA W Alberts
Mar 15, 1989·The Biochemical Journal·B KhanM Heimberg
May 28, 1970·The New England Journal of Medicine·J M Dietschy, J D Wilson
May 14, 1970·The New England Journal of Medicine·J M Dietschy, J D Wilson
May 21, 1970·The New England Journal of Medicine·J M Dietschy, J D Wilson
Jan 1, 1983·Methods in Enzymology·J L GoldsteinM S Brown
Dec 1, 1984·The Journal of Clinical Investigation·F NerviR Del Pozo
May 1, 1983·The Journal of Antibiotics·N SerizawaH Kuwano
Jul 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A W AlbertsJ Springer
Sep 1, 1955·The Journal of Clinical Investigation·R J HAVELJ H BRAGDON

❮ Previous
Next ❯

Citations

Jan 1, 1992·European Journal of Clinical Pharmacology·H Vanhanen, T A Miettinen
Dec 2, 2008·Bulletin of Experimental Biology and Medicine·Y I RaginoG A Tolstikov
Jan 16, 2009·Bulletin of Experimental Biology and Medicine·Yu I RaginoG A Tolstikov
Jul 28, 1990·Lancet·G H TomkinP Collins
Jan 1, 1995·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·A CorsiniA L Catapano
Feb 1, 1991·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·A CorsiniR Paoletti
Jan 15, 2011·Journal of Ethnopharmacology·Puttavee CharoenwanthanangSureerut Porntadavity
Jun 1, 1991·Atherosclerosis·M HorieT Kamei
Jul 11, 2006·The Spine Journal : Official Journal of the North American Spine Society·Albert Juang Ming YeeJung U Yoo
Apr 1, 1993·Arteriosclerosis and Thrombosis : a Journal of Vascular Biology·M R SomaR Paoletti
Apr 1, 1997·Journal of the American College of Nutrition·I GirouxH Jacques
Jul 1, 1997·Journal of Cardiovascular Pharmacology·S SasakiK Kuriyama
Apr 15, 1991·Biochemical Pharmacology·A SatoT Kamei

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.